Flotufolastat F-18
Flotufolastat is a third PSMA PET tracer, with a radiohybrid chemistry designed to be reused for therapy.
LIGHTHOUSE (initial staging) and SPOTLIGHT (biochemical recurrence) trials; approved May 2023. Low urinary excretion aids pelvic reading.
- Medicare
- Part B (clinician-administered)
Diagnostic radiopharmaceutical billed with the PET/CT scan under Part B; same coverage pathway as other PSMA PET agents.
- Commercial insurance
- covered with prior authorisation
Commercial plans cover PSMA PET for staging and recurrence with prior authorisation of the imaging procedure.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Diagnostic non-laboratory tests (imaging). Not medical or financial advice; verify with your plan.
- Notes
- No UK marketing authorisation as of September 2026, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
- NHS England
- Not routinely funded
Sources: NICE search: flotufolastat F-18. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2023 | PSMA PET in prostate cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Flotufolastat F-18" OR ABSTRACT:"Flotufolastat F-18" OR TITLE:"Posluma" OR ABSTRACT:"Posluma" OR TITLE:"18F-rhPSMA-7.3" OR ABSTRACT:"18F-rhPSMA-7.3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Flotufolastat F-18, not a curated reading list.
Pages like this
not linked directly; found by shared links- CompanyClarity Pharmaceuticals
Shares PSMA, PSMA PET, Prostate cancer.
- PersonJeremie Calais
Shares PSMA, PSMA PET, Prostate cancer.
- PersonThomas A. Hope
Shares PSMA, PSMA PET, Prostate cancer.
- ProductFluciclovine F-18
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Prostate cancer.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Prostate cancer.
- ProductGallium-68 gozetotide (PSMA-11)
Shares PSMA, PSMA PET, Prostate cancer.